Diabetes Mellitus in Pregnancy: November 2015
Diabetes Mellitus in Pregnancy: November 2015
Diabetes Mellitus in Pregnancy: November 2015
net/publication/283495236
CITATION READS
1 3,827
2 authors:
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Carmeline Motha on 05 November 2015.
Universal screening for GDM is with pregestational diabetes mellitus Compared to diet alone, exercise
practiced in Sri Lanka with the 75g than in women with GDM.11 with dietary modifications has been
OGTT performed at 24-28 weeks found to lead to improved glycaemic
of pregnancy while screening for MANAGEMENT OF DIABETES control. 16 The proposed mechanism
pregestational diabetes is advocated MELLITUS IN PREGNANCY for such an improvement in glycaemic
at the booking visit in women not Benefits of treating gestational diabetes control is heightened sensitivity
known to have preexisting diabetes. mellitus has been demonstrated. The of peripheral tissues to insulin.
Australian Carbohydrate Intolerance Unfortunately, researchers have not
Study in Pregnant Women (ACHOIS), been able to suggest an evidence
PATHOPHYSIOLOGY OF GDM based intervention with guidelines
found reduced perinatal morbidity
Normal pregnancy is associated and mortality when standard for frequency, intensity, time and type
with a number of changes in glucose contemporary treatment of gestational of physical activity (FITT principle
metabolism. Data from the gold diabetes mellitus was compared for exercise prescription) that would
standard of assessment of insulin with no intervention, while more achieve good glycaemic control in
action, the euglycaemic glucose clamp recently the maternal fetal medicine women with GDM. Based on the
demonstrates that insulin action network (MFMU) study confirmed available evidence on the benefits of
reduces as pregnancy progresses due that treatment of GDM is beneficial exercise in managing GDM, ADA
to the insulin resistance created by in reducing macrosomia and large for recommends moderate exercise
certain hormones. Human placental gestational age babies. 12 13 programs for women without medical
lactogen and placental production of or obstetrical complications.17
tumour necrosis alpha (TNF-alpha) Dietary intake is fundamental to
optimal pregnancy outcomes because Pharmacological intervention in
appear to play a key role in the the management of GDM is usually
development of insulin resistance. nutritional quality and quantity
have an important impact on the employed when the woman fails
Pregnancy as an insulin resistant to meet established goals with
state may reveal even the smallest overall growth and development of
the fetus. Medical nutrition therapy conventional therapy of diet and
pre existing defects in insulin exercise. It is also indicated when
secretion or insulin sensitivity and as (MNT) is the cornerstone of managing
gestational diabetes. MNT has been elevated fasting glucose levels occur
a consequence, relative β-cell failure. while on conventional therapy,
The pathophysiological changes of defined as a ‘carbohydrate controlled
meal plan that promotes adequate because dietary modification alone
GDM are similar to those observed in has limited effect on fasting levels.
type 2 diabetes mellitus, which is also nutrition with appropriate weight
gain, normoglycemia, and the absence NICE recommends immediate
characterized by peripheral insulin treatment with insulin, with or
resistance accompanied by an insulin of ketosis.’ According to the ADA
recommendations, carbohydrate without metformin, as well as MNT, to
secretory defect. At the same time women with gestational diabetes who
there are changes in fasting glucose intake should be approximately 40 %
of total calorie intake and should be have a fasting plasma glucose level of
likely reflecting an increased uptake 126mg/dl or above at diagnosis while
of glucose by the fetoplacental unit, selected from foods with low glycaemic
index values.14 In pregnant women of in those with a FBS between 100.8-
with average fasting capillary glucose 126 mg/dl at diagnosis, addition of
readings low as 56mg/dl, found in normal body weight (BMI between
18–22.9 kg/m2), the recommendation pharmacological agents to MNT is
healthy, lean, normal glucose tolerant advocated when FBS remains above
women in the third trimester of is to consume 30–32 kcal/kg body
weight, especially during the second 126mg/dl following a two week trial
pregnancy.10 with MNT alone. 8
half of pregnancy.15 All women should
receive nutritional advice, preferably Prandial insulin and basal insulins are
ADVERSE EFFECTS OF DIABETES from an appropriately skilled the two main regimens used during
MELLITUS ON PREGNANCY dietitian. Advice on individualized pregnancy. Studies have shown that
plan for weight gain and caloric needs short acting insulin analogues (lispro
The adverse consequences of and determining protein, fat, and and aspart) are more effective than
gestational diabetes mellitus has been micronutrient needs should also be regular human insulin in achieving
known for some time but was clearly provided. target glucose values and minimizing
delineated by the HAPO study. the risk of macrosomia.18 19 Because
Macrosomia, neonatal hypoglycaemia, It is also imperative to note that only
20% of subjects in the ACHOIS trial the insulin analogues have shorter
caesarean section, shoulder dystocia, durations of action and more rapid
preeclampsia, preterm delivery, and 8% of Maternal fetal Medicine
Units Network subjects required onsets of action than regular insulin,
hyperbilirubinuria and admission to they are associated with improved
the neonatal intensive care unit was insulin, implying that lifestyle
modification and dietary intervention postprandial glycaemic control and
shown to be associated with maternal less postprandial hypoglycaemia.
hyperglycaemia. will be effective in 80–90% of women
with GDM. Due to limited data on the use of
Major maternal morbidity and basal analogues in pregnancy, NICE
mortality is more common in women recommends neutral protamine
hagedorn (NPH) as the first choice had higher BMI in early pregnancy may be at risk of growth restriction
for long acting insulin during and higher baseline glucose levels.26 due to excessively tight maternal
pregnancy.20 The type of regimen Daily self monitoring of blood glucose control .31 A correlation has
and number of injections per day are glucose (fasting, premeal, postmeal been reported between ultrasound
determined based on the individual’s and bedtime at night), appears to be (USS) fetal abdominal circumference
needs and lifestyle. A basal bolus superior to intermittent monitoring of (AC) (AC>75th percentile) and high
insulin regimen (three bolus doses of plasma glucose as the hypoglycaemic amniotic fluid insulin levels in a
short acting insulin just prior to meals regimen could be tailored accordingly. recent study 30. There have been
with NPH insulin at night) or a split Consensus was reached at the fourth four randomized controlled studies
mixed dosage regimen (combination International workshop conference looking at the use of USS fetal AC as a
of short acting and intermediate acting on GDM on target capillary glucose guide to adjust the blood sugar levels.
insulin- Eg: Mixtard insulin twice values concentrations. Blood sugar
32 33 34 35
. Bonomo et al randomised 229
daily ) is used in pregnancy, though <95 mg/dl in the fasting state, <140 women to conventional treatment
the former regimen achieves better mg/dl at 1 hour, and <120 mg/dl 2 of GDM (glucose targets <90 mg/dl
glycaemic control.21 Pump therapy hours after starting the meal should (5.0 mmol/l) fasting and <120 mg/dl
(Continuous subcutaneous insulin be the treatment targets.27 In women (6.7 mmol/l) 2-hour post-prandial),
infusion- CSII) more closely mimics on insulin or glibenclamide, the or modified treatment targets based
physiological insulin secretion with blood sugar should not be allowed to on abdominal circumference on
evidence of less severe hypoglycaemia. drop below 72mg/dl.8 Urine glucose fetal ultrasound done two weekly as
CSII should be considered when monitoring is not useful though below. 35
adequate blood glucose control is not urine ketone monitoring can be • AC≥ 75th percentile: fasting< 80
obtained by multiple daily injections used in patients who are restricting mg/dl(4.4 mmol/l) and post-
of insulin without significant calories to detect insufficient caloric or prandial <100 mg/dl (5.5 mmol/l)
disabling hypoglycaemia. However, carbohydrate intake.28
benefits of CSII on glycaemic control • AC< 75th percentile: fasting< 100
during pregnancy have not been Although there is consensus about mg/dl(5.5 mmol/l) and post-
realized, with a Cochrane review postprandial glucose levels being prandial <140 mg/dl (7.8 mmol/l)
suggesting a potential increase in more important than preprandial They have reported a significant
infant birth weight associated with levels since the former correlates reduction in the percentage of LGA
CSII.22 The potential of a closed loop better with adverse neonatal events infants (7.9 vs. 17.9%), SGA infants
therapy, linking real time continuous such as fetal malformations, (6.0 vs. 9.0%), and macrosomia (3.3 vs.
glucose monitoring with insulin dose macrosomia, hypoglycaemia, and 11%) with this modified treatment. 35
adjustments to improve management shoulder dystocia, it has been debated USS fetal biometry may allow more
of diabetes during pregnancy is under as to whether glucose should be pragmatic treatment targets in some
investigation. measured one or two hours after a low risk patients, whilst tighter control
meal.29 Continuous blood glucose may be suggested for other patients
Metformin and glibenclanide are the monitoring using the continuous
two oral hypoglycaemics that can be at high risk of adverse perinatal
glucose monitoring system has outcomes.
used in pregnancy. Metformin can recently shown that glucose peaks
be used as an alternative or adjunct occur about 70 ± 13 minutes after a Fetal ultrasound assessment is
to insulin therapy. Metformin was meal in non diabetic pregnant women frequently used to estimate the fetal
shown to be similar to insulin with and after about 90 minutes in diabetic weight and wellbeing and to assist
regard to glycaemic control and women. safe prolongation of pregnancy and
neonatal outcome.23 Glibenclamide is time the date of delivery. However,
comparable to insulin in terms of birth Women with diabetes should have there is no uniform policy of frequency
outcome and glycaemic control and is contact with the joint diabetes and of USS examinations. Therefore, the
a suitable alternative to metformin.24 antenatal clinic for assessment of frequency of USS examinations should
NICE recommends glibenclamide for blood glucose control every 1–2 weeks be based on clinical indications. There
women with gestational diabetes in throughout pregnancy. is a paucity of high level evidence
whom blood glucose targets are not on the optimum gestational age for
achieved with metformin but who delivery in gestational diabetes.
TREATMENT ADJUSTMENT
decline insulin therapy or who cannot Different management strategies have
tolerate metformin. There is limited ACCORDING TO THE FETAL been adopted for pregestational or
evidence with regard to which oral BIOMETRIC PARAMETERS pre-existing diabetes. Rasmussen et al
hypoglycaemic should be selected. AND ANTENATAL FETAL noted that deaths in normally formed
Failure of glibenclamide was shown to infants occurred when there was
be higher in women with higher initial
SURVEILLANCE
clinical evidence of fetal macrosomia,
fasting glucose values above 115mg/ Despite optimum glycemic control polyhydramnios or poor metabolic
dl.25 Similarly for metformin, women there is a potential increase in the risk control. Consequently, uncomplicated
who required supplemental insulin of fetal macrosomia in women with GDM pregnancies could go up to 40
GDM.30 In contrast, some fetuses
12. Crowther CA, Hiller JE, Moss JR Effect of 25. Moore TR Glyburide for the treatment of 36. Rasmussen MJ. Firth R, Foley M. et
treatment of gestational diabetes mellitus gestational diabetes. A critical appraisal al. The timing of delivery in diabetic
on pregnancy outcomes New England Diabetes care 2007; 30 (supp2)-s209-13. pregnancy a 10 year review. Aust N Z J
journal of Medicine 2005; 352: 2477-86. 26. Rowan JA, Hague WM, Gao W et al Obstet Gynecol1992;32:313-7.
13. Kim C, Neston K, Knopp R. Gestational Metformin versus insulin for the treatment 37. Rouse DJ, Owen J Prophylactic
diabetes and the incidence of type 2 of gestational diabetes New England caesarean delivery for foetal macrosomia
diabetes: a systematic review. Diabetes journal of medicine 2008;358:2003-15. diagnosed by means of ultrasonography-
Care. 2002;25:1862–1868. 27. Metzger BE, Coustan DR. Summary A Faustian bargain? Am j Obstet Gynecol
14. Clapp JF. Effect of dietary carbohydrate and recommendations of the Fourth 1999;131:332-8.
on the glucose and insulin response International Workshop-Conference 38. Carron Brown S, Kyne-Grzebalski
to mixed caloric intake and exercise in on Gestational Diabetes Mellitus. The D, Mwangi B, Taylor R. Effect of
both nonpregnant and pregnant women. Organizing Committee. Diabetes Care. management policy upon 120 Type 1
Diabetes Care. 1998; 21 Suppl 2:B107- 1998; 21 Suppl 2:B161-7. diabetic pregnancies: Policy decisions in
12. 28. Gestational diabetes mellitus. practice. Diabet Med. 1999;16:573–8.
15. Jovanovic-Peterson L, Peterson CM. Diabetes Care. 2003; 26(supplement 39. Lindsay RS Diabetes in pregnancy –
Nutritional management of the obese 1):S103-S105. Diabetes management during labour
gestational diabetic pregnant woman. J 29. Jovanovic-Peterson L, Peterson CM, Oxford diabetes library 2012.
Am Coll Nutr. 1992; 11(3):246-50. Reed GF, Metzger BE, Mills JL, Knopp 40. Ferrara A, Peng T,Kim C Trends in
16. Jovanovic-Peterson L, Durak EP, RH et al. Maternal postprandial glucose postpartum diabetes screening and
Peterson CM. Randomized trial of levels and infant birth weight: the subsequent diabetes and impaired fasting
diet versus diet plus cardiovascular Diabetes in Early Pregnancy Study. The glucose among women with histories
conditioning on glucose levels in National Institute of Child Health and of gestational dibetes mellitus:A report
gestational diabetes. Am J Obstet Human Development--Diabetes in Early from the translating research into action
Gynecol. 1989; 161(2):415-9. Pregnancy Study. Am J Obstet Gynecol. for diabetes(TRIAD) study Diabetes care
17. Gestational diabetes mellitus. 1991; 164(1 Pt 1):103-11.
32:269-74.
Diabetes Care. 2003; 26(supplement 30. Kjos SL, Schaefer-Graf UM. Modified
41. Schaeffer-Graf UM, Hartmann
1):S103-S105. therapy for gestational diabetes using
R,Pawliczak J et al Association of breast
18. Lapolla A, Dalfrà MG, Fedele D. Insulin high risk and low risk fetal abdominal
feeding and early childhood overweight
therapy in pregnancy complicated by circumference growth to select strict
in children from mothers with gestational
diabetes: are insulin analogs a new versus relaxed maternal glycaemic
diabetes mellitus Diabetes care
tool? Diabetes Metab Res Rev. 2005; targets. Diabetes care 2007;30:5200-5.
2006;29:1105-7.
21(3):241-52. 31. Langer O, Levy J,Brustman L, et
42. Bellamy L , Casas JP, Hingorani AD et
19. Pettitt DJ, Ospina P, Kolaczynski JW, al. Glycaemic control in gestational
al Type 11 diabetes after gestational
Jovanovic L. Comparison of an insulin diabetes mellitus- how tight is tight
analog, insulin aspart, and regular human enough- small for gestational age versus diabetes mellitus a systematic review and
insulin with no insulin in gestational large for gestational age? Am J Obstet meta analysis Lancet 2009 373(9677)
diabetes mellitus. Diabetes Care. 2003; Gynecol1989;161:646-53. 1773-1779.
26(1):183-6. 32. Buchanan TA,Kjos SL, Montoro MN,et 43. Diabetes prevention program research
20. Metzger BE, Buchanan TA, Coustan DR, al. Use of foetal ultrasound to select group. Reduction in the incidence of
De Leiva A, Dunger DB, Hadden DR et al. metabolic therapy for pregnencies type 2 diabetes with lifestyle intervention
Summary and recommendations of the complicated by mild gestational diabetes. or metformin.New England journal of
Fifth International Workshop-Conference Diabetes care 1994;17:275-83. medicine 2002; 346:393-403.
on Gestational Diabetes Mellitus. 33. Kjos SL, Schaefar-Graf U, Sardesi 44. Xiang AH,Peter RK,Kjos SL, et al Effect
Diabetes Care. 2007; 30(2):S251-60. S, et al. A randomized controlled trial of pioglitazone on pancreatic beta cell
21. Nachum Z, et al. Twice daily versus using glycaemic pluss foetal ultrasound function and diabetes risk in Hispanic
four times daily insulin dose regimens parameters to determine insulin women with prior gestational diabetes
for diabetes in pregnancy: randomised therapy in gestational diabetes with 2006;55:517-22.
controlled trial. BMJ1999;319:1223–7. fasting hyperglycaemia. Diabetes care 45. Han S, Middleton P, Crowther CA
22. Farrar D, Tuffnell DJ,West J Continuous 2002;24:1904-10. Exercise for pregnant women in
subcutaneous insulin infusion vs multiple 34. Schaefar-Graf U, Kjos SL, Fauzan OH, preventing gestational diabetes mellitus
daily injections of insulin for pregnant et al. A randomized trial evaluating Cochrane database sys rev 2012:
women with diabetes. Cochrane a predominantly foetal growth- CD009021.
database sys rev3:CD005542. basedstrategy to guide management 46. Oostdam M, Van Poppel MN, Wouters
23. Gui J, Liu Q, Feng L. Metformin vs of gestational diabetes in Caucasian MG et al Interventions for preventing
insulin in the management of gestational women. Diabetes Care 2004;27:297-302. gestational diabetes mellitus: a
diabetes: a meta-analysis. PLoS One. 35. Bonomo M, Cetin I, Pisoni MP. et al. systematic review and meta analysis.
2013; 8(5):e64585. Flexible treatment of gestational diabetes Journal of womens health (Larchmt)
24. Langer O, Conway DL,Berkus MD et al. modulated on ultrasound evaluation 2011;20(10): 1551-1563.
A comparison of Glyburide and insulin of intrauterine growth: a controlled
in women with gestational diabetes randomized clinical trial. Diabetes Metab
mellitus New England journal of Medicine 2004;30:237-44.
2000;361: 1339-48.